Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of glucocorticoids on anti-infective efficacy and prognosis of children with bronchiolitis caused by Mycoplasma pneumoniae

Fei Jiang, Wenjie Mao, Yu Wan, Qianyuan Yang, Fei Fan, Zhiying Huang

Department of Pediatrics, The Affiliated Changzhou NO.2 People’s Hospital of Nanjing Medical University, Changzhou, China;

For correspondence:- Zhiying Huang Email: hzy982@njmu.edu.cn

Accepted: 25 July 2024 Published: 31 August 2024

Citation: Jiang F, Mao W, Wan Y, Yang Q, Fan F, Huang Z. Effect of glucocorticoids on anti-infective efficacy and prognosis of children with bronchiolitis caused by Mycoplasma pneumoniae. Trop J Pharm Res 2024; 23(8):1331-1336 doi: 10.4314/tjpr.v23i8.13

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of glucocorticoid administration on anti-infective efficacy and prognosis of children diagnosed with bronchiolitis caused by Mycoplasma pneumoniae (MP).

Methods: 100 children from January 2021 to June 2023 diagnosed with MP-induced bronchiolitis at the Department of Pediatrics, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China were randomized into study (n = 45) and control groups (n = 55). The study group received conventional medication (azithromycin at 10 mg/kg on the first day followed by 5 mg/kg/day for 5 days) in addition to glucocorticoids, while control group received the same conventional medication without glucocorticoids. The study group was treated with prednisone (2 mg/kg/day), once a day for 5 days. Inflammatory markers (C-reactive protein (CRP) and procalcitonin (PCT) levels) before and after treatment, duration of medication, disease course, clinical efficacy, and prognosis were compared.

Results: There was no significant difference in baseline characteristics between both groups (p > 0.05). The study group showed significantly reduced CRP and PCT levels, shorter medication and disease duration, and a higher efficacy compared to control group (p < 0.05).

Conclusions: Administration of glucocorticoids in addition to conventional medication in MP-induced bronchiolitis reduces levels of inflammatory markers, improves clinical symptoms, and enhances efficacy. Future studies using prospective, randomized controlled trials, larger sample sizes that cut across multicenter sites, standardized treatment protocols, and long-term follow-up will be required to more accurately confirm the safety and efficacy of glucocorticoids in the management of MP-induced bronchiolitis.

Keywords: Glucocorticoids, Mycoplasma pneumoniae, Bronchiolitis, Efficacy, Prognosis